Physician profile
Tara E Hahn
NPI 1174902456
$4,095.40
in general payments reported to CMS, 2019-2025
22 companies · $543 in 2025
The $543 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $327 · 2021: $636 · 2022: $542 · 2023: $1,081 · 2024: $582 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,206.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $844.33 | 2022-2024 | |
| New World Medical,INC. | $651.68 | 2021-2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Alcon Vision LLC | $607.20 | 2019-2025 | Rocklatan, Tryptyr |
| Sun Pharmaceutical Industries INC. | $390.20 | 2021-2025 | Cequa |
| Sight Sciences, INC. | $317.37 | 2019-2024 | Omni Surgical System |
| Glaukos Corporation | $216.45 | 2022-2025 | Idosetr |
| Aerie Pharmaceuticals, INC. | $185.85 | 2019-2021 | |
| Allergan, INC. | $159.98 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $149.60 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $85.37 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $79.08 | 2022-2025 | Oxervate |
| Ocular Therapeutix, INC. | $72.37 | 2025 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.99 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $50.83 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $39.49 | 2022-2025 | Catalys System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $35.69 | 2021 | |
| Apellis Pharmaceuticals, INC. | $34.44 | 2022-2023 | |
| Astellas Pharma US INC | $34.24 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $26.66 | 2021 | |
| Eyevance Pharmaceuticals LLC | $25.00 | 2021 | |
| Ivantis, INC | $18.77 | 2019 | |
| Biotissue Holdings INC. | $14.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.